Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-103

The historical data is hugely valuable. The historical data is like having access to a time machine that you can use to look years into the future and see the outcome of the clinical trials. Normally when you put a new drug into people you have no idea what will happen, what dose will be tolerable, what side effects will show up, etc. The list of things that can go wrong in the clinic is almost endless - it is a miracle any new drug ever makes it market.

Even more importantly, it gives you insight into the rare side effects that only happen in 1 in 200 or more patients. More than a few drugs have died in Phase 3 because of a rare side effect that didn't show up in the Phase 1 or 2 trials because these trials are too small.

While the regulators might consider RC220 a new drug, the active ingredient is still bisantrene and with that comes all the value of the historical data. With the new formulation we get the benefit of the historical data plus we get to reset the patent life.